CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 021068 and 18044/S025

CHEMISTRY REVIEW(S)

CHEMIST'S REVIEW	1.ORGANIZATION	2. NDA NUMBER
	DMEDP, HFD-510	18-044

3. NAME AND ADDRESS OF APPLICANT	4.SUPPLEMENT NUMBER,DATE
Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley, New Jersey 07110-1199	SEI-025 Dated: 11-18-97 User Fee Date: 11-20-98

5. NAME OF THE DRUG	6. NONPROPRIETARY NAME	
ROCALTROL®	calcitriol	
		8.AMENDMENTS/REPORT,DATE

7. SUPPLEMENT PROVIDES FOR:	
the use of Rocaltrol® in the treatment of secondary hyperparathyroidism in patients with moderate to severe chronic renal failure who are not yet undergoing dialysis. *In addition, this supplement provides for a new dosage form, an oral solution containing 1 mcg/mL calcitriol NDA 21-068*	Amendment dated 11-02-98 Amendment dated 11-12-98

9. PHARMACOLOGICAL CATEGORY	10. HOW DISPENSED	11.RELATED IND/NDA/DMF
	Rx only	

12. DOSAGE FORM	13. POTENCY
Oral solution	1 mcg per mL

NDA 21-068

14. CHEMICAL NAME AND STRUCTURE.

Calcitriol 1α,25-Dihydrocholecalciferol $C_{27}H_{44}O_3$ Mol. Wt. 416.65 g/mol

15. COMMENTS

NDA 18-804/S-025 is an efficacy supplement providing for the use of ROCALTROL® in the treatment of secondary hyperparathyroidism in pre-dialysis patients with moderate to severe chronic renal failure (Creatinine clearance of 15 - 55 mL/min). This supplement also provides for a new dosage form for the drug product, an oral solution containing 1 mcg/mL, to be packaged in 15 mL amber glass bottles, equipped with single-use 1 mL graduated oral dispensers *The new dosage form is the subject of this (Chemistry) review.* The composition of the oral solution is similar to that of the approved capsules, with four constituents, of which three are unchanged: 1) calcitriol (active ingredient); 2) butylated hydroxyanisole (BHA, an antioxidant); and 3) butylated hydroxytoluene (BHT, an antioxidant). The vehicle used for the approved capsules is a fractionated triglyceride of coconut oil _____ , _____ *,while the vehicle _____ for the proposed solution in*

(Continued on the next page)

16. CONCLUSION AND RECOMMENDATION		
Adequate information has been supplied. From the standpoint of chemistry, the supplement is approvable.		
17. NAME	REVIEWER SIGNATURE	DATE COMPLETED
David B. Lewis, Ph.D.	/S/	11-12-98

DISTRIBUTION: ORIGINAL JACKET   CSO   REVIEWER   DIVISION FILE

/S/   11/12/98

APPEARS THIS WAY
ON ORIGINAL